Skip to content

Effect of Exogenous Growth Hormone on Ocular Findings

Effect of Exogenous Growth Hormone on Ocular Findings of Children With Precocious and Early Puberty: a Prospective Cohort Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05338411
Enrollment
90
Registered
2022-04-21
Start date
2022-03-20
Completion date
2023-10-22
Last updated
2022-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Puberty, Precocious Puberty, Refraction Error

Keywords

Precocious Puberty, Early Puberty, human growth hormone, Refraction Error, Axial Length

Brief summary

Body size and eye function play an essential role in adapting to the environment and human survival. Growth hormone is commonly recognized by its effect on the height of individuals; Although from an evolutionary perspective, the effects of growth hormone on eye development are more important. Although the effect of growth hormone on eye development has not been accurately determined, the results of a number of studies suggest the effect of growth hormone on eye development. Despite the large number of studies that have investigated the effects of growth hormone on height growth, there are few studies that have investigated the effects of growth hormone on the eye. To the best of our knowledge, no study has been conducted to investigate the effect of growth hormone on ocular findings of patients with early or precocious puberty. Therefore, we intend to investigate the effect of growth hormone on ocular findings of patients with early or precocious puberty.

Detailed description

Investigators will achieve the following data from the participants: 1. Demographics 2. Past medical history 3\. Bone and calendar age 4- Stage of puberty 5- Ocular examination 6\. Ocular biometry

Interventions

None listed

Sponsors

Isfahan University of Medical Sciences
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
4 Years to 11 Years
Healthy volunteers
Yes

Inclusion criteria

Sample group (with early or precocious puberty): 1. Children with precocious puberty based on Tanner classification 2. Girls 4 to 10 years old 3. Boys aged 4 to 11 4. No known eye problems including: history of eye trauma, eye surgery 5- lack of family history of glaucoma or increased intraocular pressure 6\. Lack of previous history of receiving growth hormone 7. Lack of systemic disease or known syndromes 8. Consent to participate in the study

Exclusion criteria

1. Incidence of growth hormone adverse reactions leading to discontinuation of treatment 2. Changing the patient's treatment plan during the study 3. Ocular complications requiring treatment during the study 4. Unwillingness of the patient to continue participating in the study

Design outcomes

Primary

MeasureTime frameDescription
Refraction Error6 monthsComparison of the refraction error between the study groups
Axial Length6 monthsComparison of the axial length between the study groups

Secondary

MeasureTime frameDescription
Papillitis6 monthsComparison of the frequency of papillitis between the study groups
Central Corneal Thickness6 monthsComparison of the mean central corneal thickness between the study groups

Countries

Iran

Contacts

Primary ContactMohsen Pourazizi, MD
m.pourazizi@med.mui.ac.ir00983134452036

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026